Drug Database
PI

pitavastatin + valsartan (Livalsartan / Livasartan)

✓ Approved

JW Pharmaceutical · AGTR1 · Small Molecule

What is pitavastatin + valsartan?

pitavastatin + valsartan is a small molecule developed by JW Pharmaceutical. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesLivalsartan, Livasartan
CompanyJW Pharmaceutical
Drug ClassSmall Molecule
Molecular TargetAGTR1, HMGCR
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, JW Pharmaceutical

Mechanism of Action

Molecular Targets

pitavastatin + valsartan acts on 2 molecular targets:

AGTR1angiotensin II receptor type 1 (HAT1R, AT1)
HMGCR3-hydroxy-3-methylglutaryl-CoA reductase (LDLCQ3, LGMDR28)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

pitavastatin + valsartan is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersHypercholesterolaemia✓ Approved
Vascular disordersHypertension✓ Approved

Related Research Articles

PubMedJournal of geriatric cardiology : JGC2026-09-19

Safety and efficacy of low-density lipoprotein-lowering drugs in the elderly: a network meta-analysis of randomized controlled trials.

Niaga Karmenia Jessica Kurnia KJK, Supinto Pedro Arruda PA, Tjandra Kevin Christian KC, Martin Alfianto A et al.

Balancing the efficacy of low-density lipoprotein (LDL) reduction with safety presents a significant challenge in the elderly care. While guidelines recommended high-intensity statins as the optimal strategy to lower LDL in high-risk individuals, there are prevailing concerns regarding its side effects and subsequent fatality rate. The effectiveness of different LDL-lowering therapies in this population is also unclear. This study aims to compare the safety and efficacy of various LDL-lowering strategies in elderly population. A systematic search was conducted through six databases until March 2025. Randomized controlled trials (RCTs) that evaluate LDL-lowering agents were included. The primary outcome was adverse effects, while secondary outcomes included composite cardiovascular disease (CVD) events, CVD related mortality, all-cause mortality, and LDL level reduction. Risk of bias was assessed using the RoB-2 tool. A network meta-analyses were performed to compare the safety and efficacy with subgroup analysis based on underlying CVD under the cumulative ranking values. Sixteen RCTs (n = 43,625) with low to moderate risk of bias were included. Among interventions evaluated for adverse events, moderate-intensity pitavastatin had the highest probability of being the safest. Ezetimibe demonstrated the most favorable safety profile for reducing CVD mortality, while evolocumab was most effective in lowering all-cause mortality. For LDL reduction, the combination of moderate-intensity pitavastatin and ezetimibe was the most effective, followed by moderate-intensity rosuvastatin plus ezetimibe. Subgroup analyses revealed significant differences between CVD and non-CVD populations in CVD mortality (P = 0.0059), CVD events (P = 0.0096), and LDL reduction (P = 0.0100), with more pronounced effects in the non-CVD group, suggesting greater efficacy in primary prevention. Moderate-intensity pitavastatin showed the highest safety profile, while its combination with ezetimibe was the most effective for LDL reduction.

PMID 42760936
Read full article →
PubMedJournal of cardiovascular pharmacology2026-09-18

Effect of Sacubitril/Valsartan versus Angiotensin Receptor Blocker or Calcium Channel Blockers on Ambulatory Blood Pressure and Safety in Hypertensive Patients: A Meta-Analysis of Randomized Controlled Trials.

Li Xueyi X, Gao Lige L, Guo Wenqing W, Li Jiadi J

Sacubitril/valsartan, the first angiotensin receptor neprilysin inhibitor (ARNIs), has antihypertensive and organ-protective effects. However, previous meta-analyses have mainly compared it with angiotensin receptor blockers (ARBs) and neglected other commonly used antihypertensive agents, while its effect on ambulatory blood pressure remains unclear. This meta-analysis aimed to evaluate the efficacy and safety of sacubitril/valsartan in patients with hypertension. We searched CNKI, Wanfang, VIP, PubMed, Embase, and the Cochrane Library from inception to June 2025 for randomized controlled trials comparing sacubitril/valsartan with ARBs or calcium channel blockers (CCBs). Fifteen studies involving 4,824 hypertensive patients were included. Compared with ARBs or CCBs, sacubitril/valsartan significantly reduced 24-hour systolic variability (24hSBPV) and 24-hour diastolic blood pressure variability (24hDBPV), as well as 24-hour, daytime, and nighttime ambulatory blood pressure. It also improved the dipper blood pressure proportion and blood pressure control rate. Subgroup analysis showed that both 200 mg/d and 400 mg/d dosages achieved superior antihypertensive efficacy. In terms of safety, sacubitril/valsartan had a similar adverse event profile to CCBs. Compared with ARBs, sacubitril/valsartan at 200 mg/d was associated with a lower incidence of serious adverse events (SAE), and the overall rate of liver function abnormalities was also reduced. Sensitivity analyses confirmed robust results with no significant publication bias. In conclusion, sacubitril/valsartan effectively improves multiple ambulatory blood pressure parameters with a favorable safety profile, supporting its rational use in hypertensive patients.

PMID 42758898
Read full article →
PubMedCurrent HIV/AIDS reports2026-09-16

Primary Cardiovascular Prevention in People Living With HIV: Rethinking Statin Therapy in the Post-REPRIEVE Era.

Fusco Paolo P, De Maria Francesco F, Tassone Bruno B, Russo Alessandro A

This review examines approaches to primary cardiovascular prevention in people with HIV (PWH), focusing on the implications of the REPRIEVE trial and the 2026 ACC/AHA multisociety dyslipidemia guideline. We discuss cardiovascular risk mechanisms, limitations of conventional prediction tools, selection and monitoring of statin therapy, and the potential roles of imaging and non-statin lipid-lowering agents. REPRIEVE demonstrated that pitavastatin reduced major adverse cardiovascular events in PWH aged 40-75 years receiving antiretroviral therapy and at low-to-moderate estimated cardiovascular risk. Absolute benefit varied substantially according to baseline risk. Current US guidance recommends statin therapy for primary prevention in PWH aged 40-75 years receiving stable combination antiretroviral therapy, while quantitative risk assessment remains important for communicating expected benefit and informing treatment intensity. REPRIEVE did not directly study PWH younger than 40 years or older than 75 years; however, cohort data suggest a higher HIV-attributable relative cardiovascular risk at younger ages despite low absolute event rates, whereas general-population evidence supports statin efficacy and acceptable tolerability in older adults. Conventional risk models show variable performance in PWH, and high-quality evidence supporting imaging-guided prevention or non-statin cardiovascular outcome reduction specifically in this population remains limited. Statin therapy is an evidence-based component of primary cardiovascular prevention in PWH aged 40-75 years, but guideline-level eligibility does not imply uniform absolute benefit. Outside the REPRIEVE age range, decisions should integrate the distinct balance of relative and absolute risk, general-population evidence, comorbidity, frailty, drug-drug interactions, treatment burden, and individual preferences rather than rely on age alone.

PMID 42747751
Read full article →
PubMedAnimals : an open access journal from MDPI2026-09-15

Long-Term Control of Refractory Cardiogenic Pleural Effusion in a Cat Treated with Sacubitril/Valsartan and Hydrochlorothiazide: A Case Report.

Maftei Mălina-Cristina MC, Scîntei Laura Marina LM, Beschea Chiriac Sorin Ioan SI, Vulpe Vasile V et al.

Sacubitril/valsartan is an angiotensin receptor-neprilysin inhibitor (ARNI) widely used in human heart failure and has demonstrated potential cardiorenal and neurohormonal effects in experimental canine studies. Hydrochlorothiazide is a thiazide diuretic that acts at a more distal segment of the nephron than furosemide. Its addition to loop diuretic therapy may enhance sodium and fluid excretion through sequential nephron blockade and thereby improve the diuretic response in cases of refractory congestion. However, information regarding the combination of these two drugs in cats with congestive heart failure is lacking. This report describes the long-term clinical outcome of a cat with recurrent cardiogenic pleural effusion treated with sacubitril/valsartan and hydrochlorothiazide. A 14-year-old spayed female Persian-cross cat was referred for severe respiratory distress caused by recurrent pleural effusion. Echocardiography identified advanced cardiomyopathy with a nonspecific phenotype and overlapping hypertrophic and restrictive features, including focal basal septal hypertrophy, biatrial enlargement, atrial fibrillation and spontaneous echocardiographic contrast. Despite conventional treatment, which included pimobendan, torasemide, and antithrombotic medications, the cat experienced multiple episodes of pleural effusion over the following months, requiring repeated thoracocentesis. Consequently, the treatment regimen was expanded to include sacubitril/valsartan and hydrochlorothiazide. According to the owner, all other cardiac medications were discontinued approximately one week later without veterinary consultation. At long-term follow-up approximately two years after sacubitril/valsartan and hydrochlorothiazide therapy initiation, the cat remained clinically stable, with no further episodes of respiratory distress. Echocardiography revealed persistent severe structural heart disease, although improved left ventricular systolic indices were observed. This case report describes prolonged clinical stabilization in a cat with advanced cardiomyopathy and recurrent congestive heart failure following the administration of sacubitril/valsartan and hydrochlorothiazide over a two-year period. Whether this outcome reflects a specific effect of sacubitril/valsartan, the addition of hydrochlorothiazide, or a combination of both cannot be determined from a single observation. Nonetheless, the duration and completeness of the response observed here warrant prospective evaluation of combination of ARNI therapy and hydrochlorothiazide in cats with refractory congestive heart failure. Further studies are needed to assess the safety and effectiveness of this approach in feline cardiomyopathy.

PMID 42738489
Read full article →
PubMedJournal of human hypertension2026-09-15

Comparison of telmisartan with losartan, valsartan, and candesartan on the risk of new-onset diabetes mellitus.

Chu Hyun-Wook HW, Choi Hyejung H, Seo Won-Woo WW, Cho Jeonghwan J et al.

Evidence remains limited on whether telmisartan with partial peroxisome proliferator-activated receptor-gamma (PPAR-γ) activity lowers new-onset diabetes mellitus (NODM) risk compared with non-PPAR-γ-active angiotensin II receptor blocker (ARB). We therefore evaluated the NODM risk of telmisartan compared with losartan, valsartan, and candesartan using real-world clinical data. We conducted a multicenter, retrospective, treatment-control cohort study using clinical data from 17 institutions between 2005 and 2023, covering 19 283 922 patients converted to a common data model. Adults newly prescribed telmisartan or other ARBs (losartan, valsartan, or candesartan) and taking the medication for ≥6 months were included, while patients with pre-existing diabetes were excluded. Propensity score matching (PSM) was performed, and hazard ratios (HR) were estimated using a Cox proportional hazards model. The primary outcome was incident NODM, defined by a diagnosis of diabetes (ICD-10), initiation of glucose-lowering medications, or HbA1c ≥ 6.5%. A total of 6 868 patients of new-users of telmisartan and 22 500 patients of other ARBs were included. In the overall population, telmisartan was associated with lower NODM risk (HR 0.87, 95% CI 0.80-0.94). After 1:2 PSM, there was no significant difference in the risk of NODM between telmisartan and other ARBs (10.61% [39.50/1 000 person-years] vs. 11.02% [40.42/1 000 person-years]; HR 0.97, 95% CI 0.88-1.08). Secondary analyses were also not significantly different. Overall, this study did not detect sufficient evidence that telmisartan reduces NODM risk compared with losartan, valsartan, or candesartan.

PMID 42736363
Read full article →
PubMedFrontiers in pharmacology2026-09-13

A microdose cocktail and population pharmacokinetic study suggests potentially reduced CYP3A and P-gp activities in type 2 diabetes.

Li Yafen Y, Yang Jin J, Zhou Enda E, Geng Kuo K et al.

Diabetes patients often exhibit suboptimal efficacy and adverse reactions, accompanied by pharmacokinetic (PK) changes, indicating drug-metabolizing enzymes and transporters (DMET) activities may change. This study aimed to determine whether type 2 diabetes affects DMET activities and quantify impact magnitude. Furthermore, gut microbiome, pharmacogenetic and demographic characteristics were assessed to elucidate the sources of inter-individual variability (IIV) in DMET activities. The activities of CYP3A and transporters P-gp, OATP and BCRP were evaluated in type 2 diabetes patients and healthy volunteers (HVs) following a single oral dose of five probe drugs (midazolam, dabigatran etexilate, pitavastatin, rosuvastatin, and atorvastatin). Population pharmacokinetics (PopPK) and an exploratory machine learning (ML) analysis were employed to quantify the impact of type 2 diabetes on DMET activities. Based on observed PK parameters, compared to HVs, type 2 diabetes patients exhibited increased exposure to midazolam (1.38-fold), dabigatran (1.40-fold), and atorvastatin (1.93-fold), whereas pitavastatin (0.931-fold) and rosuvastatin (1.25-fold) showed no change. PopPK analysis revealed that the mean activities of CYP3A and P-gp were potentially decreased by 23% and 27%, respectively, in type 2 diabetes patients, while no changes for OATP and BCRP. Notably, unlike the direct patient population covariate for P-gp, reduced CYP3A activity was indirectly estimated from lower Salmonella abundance. Additionally, factors such as sex, BCRP genotype, and Clostridium_XlVb partly explained the IIV in probe drugs exposure. The findings regarding altered DMET activities and identified influence factors help to identify specific drug classes that may warrant closer clinical attention in type 2 diabetes patients.

PMID 42729281
Read full article →

+7406 more articles available with a free account

Sign up free to view all articles →

Ask about pitavastatin + valsartan